We are live on
!
Find out more
SRC
Shufro Rose & Co Portfolio holdings
AUM
$1.47B
1-Year Est. Return
19.38%
This Fund
S&P 500
This Quarter
Est. Return
+10.61%
1 Year Est. Return
+19.38%
3 Year Est. Return
+47.49%
5 Year Est. Return
+55.37%
10 Year Est. Return
+200.77%
AUM
$947M
AUM Growth
+$67.9M
(+7.7%)
Cap. Flow
-$19M
Cap. Flow
% of AUM
-2.01%
Top 10 Holdings %
Top 10 Hldgs %
31.65%
Holding
277
New
24
Increased
72
Reduced
85
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
COL
Rockwell Collins
COL
|
+$10.4M |
| 2 |
LTM
LIFE TIME FITNESS INC
LTM
|
+$10.1M |
| 3 |
Valmont Industries
VMI
|
+$7.73M |
| 4 |
Darling Ingredients
DAR
|
+$6.27M |
| 5 |
PERY
Perry Ellis International Inc
PERY
|
+$1.66M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$16.1M |
| 2 |
Exelon
EXC
|
+$6.81M |
| 3 |
Crocs
CROX
|
+$5.78M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$5.63M |
| 5 |
Avery Dennison
AVY
|
+$5.52M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.01% |
| 2 | Industrials | 17.97% |
| 3 | Healthcare | 12.8% |
| 4 | Consumer Discretionary | 12.43% |
| 5 | Energy | 8.73% |
Similar funds
SVWAG
KRSITF
CWM
AAIM
SWA
VCP
PWMAG
ACM
Shufro Rose & Co's Q4 2013 Portfolio in Review
As of Q4 2013, Shufro Rose & Co held 277 positions worth $947M, up 7.7% from $879M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Shufro Rose & Co's Q4 2013 filing shows 24 new, 72 increased, 85 reduced and 14 closed positions. Its largest new stake was Rockwell Collins: 145,705 shares worth $10.8M. The largest sale was Teva Pharmaceuticals, an estimated $16.1M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 21% a quarter earlier, followed by Industrials and Healthcare.
- Shufro Rose & Co's largest Q4 2013 buy was Rockwell Collins: 145,705 shares worth $10.8M.
- Shufro Rose & Co added most to Vishay Precision Group in Q4 2013, an estimated $1.63M increase.
- Shufro Rose & Co's biggest Q4 2013 reduction was Teva Pharmaceuticals, cutting an estimated $16.1M.
- Shufro Rose & Co fully exited MAIDENFORM BRANDS, INC in Q4 2013, selling an estimated $4.49M.
- Shufro Rose & Co's ten largest holdings make up 32% of its $947M portfolio in Q4 2013.
- Shufro Rose & Co opened 24 new positions and closed 14 in Q4 2013.
- Shufro Rose & Co's portfolio value rose 7.7% quarter-over-quarter to $947M.
Based on Shufro Rose & Co's 13F filing for Q4 2013, filed 4 Feb 2014.